October 1, 2018 | Jennifer Guinan IntegriChain’s Dave Weiss to Chair 340B Track at Medicaid Drug Rebate Program Summit IntegriChain announces that Dave Weiss, Executive Director of Industry Solutions and industry expert on 340B analytics, will chair the 340B Track at the Medicaid Drug Rebate Program Summit (MDRP). The MDRP 340B track is slated for October 2 from 1:45 pm to 5:20 pm, and 340B sessions dominate this year’s MDRP agenda overall. Read More Tags: 340B, MDRP, speaker
September 26, 2018 | Brandon Underwood Frequently Asked Questions – 340B Program The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is taken from the Q&A session of IntegriChain's recent 340B webinar. Topics discussed include growth in contract pharmacies/covered entities, 340B discount pricing for orphan drugs, and validation of 340B entities. Read More Tags: 340B, 867, contract pharmacy, covered entity, Diversion, Duplicate Discounts, Enriched 867 Data, National data, Orphan Drugs, Subnational data
December 16, 2015 | Dave Weiss Troubling Results of HRSA’s 2015 Program Integrity Audits Posted on November 25 While we applaud the Health Resources and Services Administration (HRSA) for its efforts to create more transparency in the 340B program through its proposed guidance and program integrity initiative, a quick inspection of the 2015 audit results posted on the Office of Pharmacy Affairs (OPA) website is deeply concerning. As part of this report, HRSA audited 137 covered entities in 2015, which was a 30% increase above 2014. If the results are extrapolated to the universe of 30,000+ covered entities (and their associated contract pharmacies) then the level of potential abuse is far worse than even its harshest critics could […] Read More Tags: 340B, chargebacks
July 9, 2015 | Dave Weiss GAO 340B Report: The Debate on Whether 340B Financial Incentives Create “Big Hospitals” For those of us who monitor the 340B Drug Pricing Program, a fascinating report and industry debate erupted this week over the June 2015 US Government Accountability Office (GAO) Report to Congress entitled “Medicare Part B Drugs: Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals." Debate has broken out after the report showed that while charitable and unreimbursed care are in fact higher at 340B hospitals, especially at those with higher Disproportionate Share Hospital (DSH) adjustments, some notable facts and trends in the program have emerged. Read More Tags: 340B, drug pricing discount program, revenue leakage
